Plain-English translation of NCT06665646 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new HIV prevention vaccine called paired with an immune booster called Hiltonol. The study includes people who already participated in an earlier trial of this same vaccine, and researchers want to see if the vaccine continues to be safe and how well it helps the immune system recognize and fight HIV.
HIV remains a serious public health challenge, and an effective vaccine could prevent millions of infections worldwide. This trial builds on earlier work to see whether this medication can safely help your body's immune system protect against HIV infection.
You likely qualify if…
You likely don't qualify if…
You will receive three injections of the vaccine (or a placebo, depending on which group you were in during the earlier study) at weeks 0, 4, and 24. You'll attend clinic visits for safety checks, blood tests, and to answer questions about how you're feeling. You'll also have a small tissue sample collected from your arm at one visit. The study lasts about one year, with follow-up contact at 12 months after your last injection.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States